Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
IPO Year:
Exchange: NYSE
Website: danaher.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/11/2026 | $200.00 | Neutral | Piper Sandler |
| 6/3/2026 | $210.00 | Buy | DZ Bank |
| 6/2/2026 | Peer Perform | Wolfe Research | |
| 5/26/2026 | $230.00 | Buy | Citigroup |
| 5/15/2026 | $200.00 | Outperform | RBC Capital Mkts |
| 12/9/2025 | $265.00 | Buy | Goldman |
| 12/2/2025 | $270.00 | Overweight | Morgan Stanley |
| 10/8/2025 | $220.00 | Buy → Neutral | Rothschild & Co Redburn |
| 7/11/2025 | $275.00 | Sector Perform → Sector Outperform | Scotiabank |
| 4/10/2025 | $205.00 | Equal Weight → Overweight | Barclays |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Piper Sandler initiated coverage of Danaher with a rating of Neutral and set a new price target of $200.00
DZ Bank initiated coverage of Danaher with a rating of Buy and set a new price target of $210.00
Wolfe Research resumed coverage of Danaher with a rating of Peer Perform
Citigroup resumed coverage of Danaher with a rating of Buy and set a new price target of $230.00
RBC Capital Mkts resumed coverage of Danaher with a rating of Outperform and set a new price target of $200.00
Goldman initiated coverage of Danaher with a rating of Buy and set a new price target of $265.00
Morgan Stanley initiated coverage of Danaher with a rating of Overweight and set a new price target of $270.00
Rothschild & Co Redburn downgraded Danaher from Buy to Neutral and set a new price target of $220.00
Scotiabank upgraded Danaher from Sector Perform to Sector Outperform and set a new price target of $275.00
Barclays upgraded Danaher from Equal Weight to Overweight and set a new price target of $205.00
8-K - DANAHER CORP /DE/ (0000313616) (Filer)
11-K - DANAHER CORP /DE/ (0000313616) (Filer)
S-8 - DANAHER CORP /DE/ (0000313616) (Filer)
8-K - DANAHER CORP /DE/ (0000313616) (Filer)
SD - DANAHER CORP /DE/ (0000313616) (Filer)
8-K - DANAHER CORP /DE/ (0000313616) (Filer)
CERT - DANAHER CORP /DE/ (0000313616) (Filer)
8-A12B - DANAHER CORP /DE/ (0000313616) (Filer)
8-K - DANAHER CORP /DE/ (0000313616) (Filer)
424B5 - DANAHER CORP /DE/ (0000313616) (Filer)
Fastest customizable press release news feed in the world
WASHINGTON, July 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted. Key Second Quarter 2026 ResultsNet earnings were $870 million, or $1.23 per diluted common share, up 60% year-over-year.Non-GAAP adjusted diluted net earnings per common share grew 8.0% to $1.94.Revenues increased 5.5% year-over-year to $6.3 billion.Non-GAAP core revenue increased 3.0% year-over-year and non-GAAP core revenue excluding respiratory testing revenue increased 4.5% year-over-year.Operating cash flow was $1.5 billion an
Linden Capital Partners ("Linden") and Audax Private Equity ("Audax"), two leading middle-market private equity firms, announced today an agreement to sell StatLab Medical Products ("StatLab" or the "Company") to Leica Biosystems, an operating company of Danaher Corporation (NYSE:DHR). The transaction is subject to customary closing conditions. Founded in 1976 and headquartered in McKinney, Texas, StatLab is a leading manufacturer of pre-analytical products spanning the full anatomic pathology workflow, delivering high-quality products and expert service to laboratories and OEM customers across the United States and Europe. During the ownership of Audax and Linden, StatLab expanded from a
WASHINGTON, June 29, 2026 /PRNewswire/ -- The Danaher Foundation, supported by Danaher Corporation (NYSE:DHR), today announced a $1 million commitment to support urgent, on-the-ground response to the Ebola Bundibugyo outbreak in the Democratic Republic of Congo (DRC) and Uganda through Save the Children, the International Rescue Committee (IRC) and the World Food Program USA in support of the World Food Programme (WFP). The funding will be distributed across the three organizations to enable rapid, flexible response to evolving conditions on the ground. Efforts will focus on critical needs including infection prevention, hygiene support, community-based health services and emergency food ass
WASHINGTON, June 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2026 on Tuesday, July 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.You can
Powered by smartSET™, the Pattern Recognition Capability Analyzes Continuous Patient Data to Provide Clinicians With Earlier Insight Into Opioid-Related Respiratory Risk Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, today announced FDA 510(k) clearance for an opioid-induced respiratory depression detection capability integrated into the Radius VSM® wearable continuous patient monitor. Enabled by Masimo’s next-generation smartSET™ pulse oximetry sensor platform, the new feature uses advanced pattern recognition that analyzes continuous physiologic data to help clinicians identify early signs of respirator
WASHINGTON, June 10, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has completed the acquisition of Masimo Corporation, a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings. Masimo's trusted brand, advanced sensor technology and AI-enabled patient monitoring bring complementary and powerful new capabilities to the Danaher diagnostics portfolio. As a result of the transaction, Masimo is now a wholly-owned subsidiary of Danaher and Masimo common stock has ceased trading on the Nasdaq Stock Market. Masimo will continue to operate unde
NEW YORK, June 8, 2026 /PRNewswire/ -- Sirius XM Holdings Inc. (NASD: SIRI) will replace Masimo Corp. (NASD: MASI) in the S&P MidCap 400 effective prior to the opening of trading on Thursday, June 11. S&P 500 & 100 constituent Danaher Corp. (NYSE:DHR) is acquiring Masimo in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective Date Index Name Action Company Name Ticker GICS Sector June 11, 2026 S&P MidCap 400 Addition Sirius XM HoldingsSIRI Communication Services June 11, 2026 S&P MidCap 400 Deletion MasimoMASI Health Care ABOUT S&P DOW JONES INDICESS&P Dow Jon
At ASMS, SCIEX, a Danaher company and leader in life science analytical technologies, launched the novus V55 system - a next-generation triple quadrupole mass spectrometer designed for the realities of high-pressure, results-driven labs. The system provides exceptional sensitivity and accelerated output, in a smaller footprint and with improved energy efficiency when compared to the SCIEX 5500+ system. This quantitative solution expands testing capabilities across pesticide and food analysis, pharmaceutical impurities, bioanalysis, PFAS testing and additional applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601916
At ASMS, SCIEX, a Danaher company and leader in life science analytical technologies, introduced platform-wide advancements across its accurate mass ZenoTOF line. The updates include new SCIEX OS 5.0 software features, broader front-end compatibility, and forward-looking software collaborations designed to help omics researchers solve complex biological questions. This connected environment reduces workflow complexity, while enabling deeper, more actionable insights from a single, dynamic platform. SCIEX OS 5.0 software introduces new features including Central Metrics Tracker, Central Monitoring, Reporter Template Creator, an AI enabled "helpme" function, and AI enabled Calculated Column
Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected William K. "Dan" Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired from the Board following 44 years as a Director of Henry Schein and was named Chairman Emeritus in recognition of his extraordinary contributions to the Company. Mr. Daniel joined the Henry Schein Board of Directors in May 2025. He possesses decades of board and global executive leadership experience in healthcare and industrial sectors, including serving for 14
Live Leadership Updates
NEW YORK, June 8, 2026 /PRNewswire/ -- Sirius XM Holdings Inc. (NASD: SIRI) will replace Masimo Corp. (NASD: MASI) in the S&P MidCap 400 effective prior to the opening of trading on Thursday, June 11. S&P 500 & 100 constituent Danaher Corp. (NYSE:DHR) is acquiring Masimo in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective Date Index Name Action Company Name Ticker GICS Sector June 11, 2026 S&P MidCap 400 Addition Sirius XM HoldingsSIRI Communication Services June 11, 2026 S&P MidCap 400 Deletion MasimoMASI Health Care ABOUT S&P DOW JONES INDICESS&P Dow Jon
WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2
Leverages Mr. Ittmann's extensive print industry and international business experience Padraig Finn, with over 16 years in the print industry, promoted to Senior Vice President, Product Identification Tom Carll, Senior Vice President, Aerospace, Thomas DeByle, CFO, and Michael Natalizia, Chief Technology Officer, round out the Executive Leadership Team Darius G. Nevin appointed Executive Chairman AstroNova, Inc. (NASDAQ:ALOT), a leading innovator in specialized print technology solutions that enable data visualization, today announced that the Board of Directors has promoted Jorik E. Ittmann to President and CEO and appointed him to the Board of Directors, both to be effective
WASHINGTON, July 31, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Jonathan Leiken has been appointed Senior Vice President and General Counsel, effective August 25, 2025. Mr. Leiken will report directly to President and Chief Executive Officer Rainer Blair and will serve as an executive officer and a member of the Danaher Leadership Team. Jonathan Leiken succeeds Brian Ellis, who will retire after nearly a decade of distinguished service as Danaher's General Counsel. Mr. Ellis will remain at Danaher in an executive officer role through February 2026 to support the transition. "Jon brings nearly three deca
WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer. This appointment marks a pivotal step in Danaher's digital transformation and its ambition to lead the next era of innovation in life sciences and diagnostics. Under Dr. Stumpe's leadership, Danaher will seek to accelerate the integration of AI across its global businesses—unlocking new levels of scientific discovery, operational efficiency and clinical impact. "Danaher i
WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021. With this expanded role, he will become an executive officer of Danaher and will continue reporting to Rainer Blair, President and Chief Executive Officer. "Greg has played a pivotal role in advancing our Life Sciences Innovations Group over the past f
WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Committee. Mr. Lamanna is currently Corporate Vice President, Business & Industry Copilot at Microsoft (NASDAQ:MSFT), where he drives product innovation in AI-powered business applications, low-code platforms, and autonomous agents. He oversees the design, product development, and engineering of some of Microsoft's most transformative technologies, including Power Platform, Dynamics 365, and Copilot Studio. Prior to that, Mr. Lamanna was the founder and CEO of MetricsHub, one of the first public cloud
Patrick Merrin named Chief Operations Officer and Peter Fjellman named Chief Financial Officer Compass Minerals (NYSE:CMP), a leading global provider of essential minerals, today announced the appointment of Patrick Merrin, a seasoned operating executive in the mining industry, as the company's new chief operations officer (COO) and Peter Fjellman, who has decades of experience in senior finance roles, as its new chief financial officer (CFO). Merrin's appointment is effective March 3 and fills the COO position which has been open since June 2024. Fjellman, whose appointment is effective immediately, succeeds Jeff Cathey who has decided to depart Compass Minerals due to personal reasons.
DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together under a single roof.WASHINGTON, July 17, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher"), a global science and technology innovator, announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs intended to accelerate the development of Companion Diagnostics (C
WASHINGTON, June 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13 years of service. Ms. Sawyer Montgomery, currently Vice President and Group Executive of Danaher's Clinical Diagnostics businesses, will become an executive officer of Danaher reporting to President and Chief Executive Officer, Rainer Blair. Rainer Blair com
Live finance-specific insights
WASHINGTON, July 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted. Key Second Quarter 2026 ResultsNet earnings were $870 million, or $1.23 per diluted common share, up 60% year-over-year.Non-GAAP adjusted diluted net earnings per common share grew 8.0% to $1.94.Revenues increased 5.5% year-over-year to $6.3 billion.Non-GAAP core revenue increased 3.0% year-over-year and non-GAAP core revenue excluding respiratory testing revenue increased 4.5% year-over-year.Operating cash flow was $1.5 billion an
WASHINGTON, June 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2026 on Tuesday, July 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.You can
WASHINGTON, June 10, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has completed the acquisition of Masimo Corporation, a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings. Masimo's trusted brand, advanced sensor technology and AI-enabled patient monitoring bring complementary and powerful new capabilities to the Danaher diagnostics portfolio. As a result of the transaction, Masimo is now a wholly-owned subsidiary of Danaher and Masimo common stock has ceased trading on the Nasdaq Stock Market. Masimo will continue to operate unde
WASHINGTON, May 5, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 31, 2026 to holders of record on June 26, 2026. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.Pow
WASHINGTON, April 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the first quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted. Key First Quarter 2026 ResultsNet earnings were $1.0 billion, or $1.45 per diluted common share.Non-GAAP adjusted diluted net earnings per common share grew 9.5% to $2.06.Revenues increased 3.5% year-over-year to $6.0 billion and non-GAAP core revenue increased 0.5% year-over-year.Operating cash flow was $1.3 billion and non-GAAP free cash flow was $1.1 billion.Strong Q1 earnings performance enabling increased full year 2026 adju
WASHINGTON, March 20, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2026 on Tuesday, April 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.You ca
WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and
Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction"). The Transaction has been unanimously approved by both Masimo's Board of Directors and Danaher's Board of Directors. Masimo will become a standalone business unit and brand within Danaher's Diagnostics segment and will operate autonomously while strengthening Danaher's offering in acute care settings. Katie Szyman, Chief Executive Officer of Masimo, stated: "We loo
WASHINGTON, Jan. 28, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted. Key Fourth Quarter 2025 Results Net earnings were $1.2 billion, or $1.66 per diluted common share.Non-GAAP adjusted diluted net earnings per common share grew 4.0% to $2.23.Revenues increased 4.5% year-over-year to $6.8 billion and non-GAAP core revenue increased 2.5% year-over-year.Operating cash flow was $2.1 billion and non-GAAP free cash flow was $1.8 billion.Key Full Year 2025 Results Net earni
WASHINGTON, Jan. 12, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2025 performance in a presentation at the J.P. Morgan Healthcare Conference at 11:15 a.m. PT. For the fourth quarter 2025, estimated revenues are anticipated to increase in the mid-single digit percent range year-over-year.Estimated non-GAAP core revenue growth for the fourth quarter of 2025 is expected to be toward the high-end of our previously announced low-single digit percentage guidance.For the full year 2025, anticipated non-GAAP adjusted diluted net earnings per common
This live feed shows all institutional transactions in real time.
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)